COCP - Research - Cocrystal Pharma Inc. (COCP) - Cocrystaling to combat viral diseases Initiating Coverage

Initiation of Coverage. We are initiating coverage on Cocrystal Pharma (COCP) with an Outperform rating and a $5 price target. In our view, Cocrystal remains under the Street's radar with its pipeline. Its versatile technology platform enables growth in new directions. As we look forward, we believe that three ongoing preclinical programs (influenza, coronavirus, and norovirus) may provide dynamic catalysts for the near/medium term. In addition, one IND filing (influenza program), expected in Q4 2020, provides fundamental depth to future value.Read More >>